Compass therapeutics announces $80 million private placement

Boston, nov. 02, 2022 (globe newswire) -- compass therapeutics, inc. (nasdaq: cmpx), (“compass”), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer, today announced that it has entered into a securities purchase agreement with a select group of institutional investors to issue and sell an aggregate of 25,000,000 shares of its common stock at an offering price of $3.21 per share through a private investment in public equity (“pipe”) financing. compass anticipates the gross proceeds from the pipe to be approximately $80 million, before deducting fees to the placement agents and other offering expenses. the closing of the financing is expected to occur by november 8, 2022, subject to the satisfaction of customary closing conditions.
CMPX Ratings Summary
CMPX Quant Ranking